Joint recommendations for the diagnosis and treatment of vulvo-vaginal atrophy in women in the peri- and post-menopausal phases from the Societa Italiana per la Menopausa (SIM) and the Societa Italiana della Terza Eta (SIGiTE)

被引:15
作者
Cagnacci, Angelo [1 ]
Gallo, Mario [2 ]
Gambacciani, Marco [3 ]
Lello, Stefano [4 ]
Gambacciani, M. [5 ]
Volpe, A. [5 ]
Cagnacci, A. [5 ]
Lanzone, A. [5 ]
Di Carlo, C. [5 ]
De Leo, V [5 ]
Biglia, N. [5 ]
Caruso, S. [5 ]
Cicinelli, E. [5 ]
Farris, M. [5 ]
Gambera, A. [5 ]
Guaschino, S. [5 ]
Paoletti, A. M. [5 ]
Russo, N. [5 ]
Vicariotto, F. [5 ]
Villa, P. [5 ]
Gallo, M. [6 ]
Nocera, F. [6 ]
Maffei, S. [6 ]
Pandolfo, M. [6 ]
Lello, S. [6 ]
Ambroggio, S. [6 ]
Grassi, G. [6 ]
De Seta, F. [6 ]
Stoniati, M. [6 ]
Gullo, D. [6 ]
Becorpi, A. [6 ]
Cancellieri, F. [6 ]
Fiorillo, F. [6 ]
Del Pup, L. [6 ]
Mapell, C. [6 ]
Ottanelli, S. [6 ]
机构
[1] San Martino Hosp, Dept Obstet & Gynecol, Genoa, Italy
[2] Presidio Osped Riunito Cirie Lanzo, Dept Obstet & Gynecol, Turin, Italy
[3] Pisa Univ Hosp, Menopause Ctr, Dept Obstet & Gynecol, Pisa, Italy
[4] A Gemelli Polyclin, Dept Womens & Childrens Hlth, Rome, Italy
[5] SIM, Rome, Italy
[6] Soc Italian Ginecol Terza Eta SIGiTE, Pisa, Italy
来源
MINERVA GINECOLOGICA | 2019年 / 71卷 / 05期
关键词
Atrophy; Postmenopause; Diagnosis; Guideline; Quality of life; GENITOURINARY SYNDROME; ESTROGEN; SYMPTOMS; CREAM; PRASTERONE; MANAGEMENT; ESTRADIOL; EFFICACY; THERAPY; ESTRIOL;
D O I
10.23736/S0026-4784.19.04469-1
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Herein, joint recommendations for diagnosis and treatment of vulvo-vaginal atrophy (VVA) in women in the peri- and post-menopausal phases from the Societa Italians per la Menopausa (SIM) and the Societa Italiana della Terza Eta (SIGiTE) are presented. The recommendations are aimed at all healthcare personnel caring for women in the menopausal transition or postmenopausal phase, and are also intended to raise awareness of VVA. Recent data clearly indicate VVA is a highly prevalent condition among postmenopausal women, and that the vast majority of women with VVA are not adequately treated. In reality, diagnosis of VVA is simple and largely clinical. Many types of treatments are available for VVA, ranging from preventive education measures to local non-hormonal therapies, local agents that modulate hormonal receptors and systemic as well as laser therapy and radiofrequency. Regardless of the therapeutic approach adopted, greater communication between the physician and the woman with VVA should be actively encouraged. This is also in light of the difficulty of talking about the VVA and related disorders. Greater communication also encourages adequate therapy and thus minimizes the impact of VVA on the quality of life of the woman and her partner.
引用
收藏
页码:345 / 352
页数:8
相关论文
共 42 条
[1]  
[Anonymous], 2012, World health organization
[2]  
[Anonymous], 2013, MENOPAUSE, V888, P902
[3]   Comparison of intravaginal 6.5 mg (0.50%) prasterone, 0.3 mg conjugated estrogens and 10 μg estradiol on symptoms of vulvovaginal atrophy [J].
Archer, David F. ;
Labrie, Fernand ;
Montesino, Marlene ;
Martel, Celine .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2017, 174 :1-8
[4]   Microdose transdermal estrogen therapy for relief of vulvovaginal symptoms in postmenopausal women [J].
Bachmann, Gloria A. ;
Schaefers, Matthias ;
Uddin, Alkaz ;
Utian, Wulf H. .
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2009, 16 (05) :877-882
[5]   Continuous low dose estradiol released from a vaginal ring versus estriol vaginal cream for urogenital atrophy [J].
Barentsen, R ;
vandeWeijer, PHM ;
Schram, JHN .
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 1997, 71 (01) :73-80
[6]   Systemic and local effects of vaginal dehydroepiandrosterone (DHEA): NCCTG N10C1 (Alliance) [J].
Barton, Debra L. ;
Shuster, Lynne T. ;
Dockter, Travis ;
Atherton, Pamela J. ;
Thielen, Jacqueline ;
Birrell, Stephen N. ;
Sood, Richa ;
Griffin, Patricia ;
Terstriep, Shelby A. ;
Mattar, Bassam ;
Lafky, Jacqueline M. ;
Loprinzi, Charles L. .
SUPPORTIVE CARE IN CANCER, 2018, 26 (04) :1335-1343
[7]   A systematic review of intravaginal testosterone for the treatment of vulvovaginal atrophy [J].
Bell, Robin J. ;
Rizvi, Farwa ;
Islam, Rakabul M. ;
Davis, Susan R. .
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2018, 25 (06) :704-709
[8]   Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study [J].
Biglia, Nicoletta ;
Peano, Elisa ;
Sgandurra, Paola ;
Moggio, Giulia ;
Panuccio, Enrico ;
Migliardi, Marco ;
Ravarino, Nicoletta ;
Ponzone, Riccardo ;
Sismondi, Piero .
GYNECOLOGICAL ENDOCRINOLOGY, 2010, 26 (06) :404-412
[9]   Systematic indirect comparison of ospemifene versus local estrogens for vulvar and vaginal atrophy [J].
Bruyniks, N. ;
Biglia, N. ;
Palacios, S. ;
Mueck, A. O. .
CLIMACTERIC, 2017, 20 (03) :195-204
[10]  
BRUYNIKS N, 2018, J GYNECOL WOM HLTH, V9, P1